Collegium Pharma (NASDAQ: COLL) reported Q2 EPS of ($0.40), $0.02 better than the analyst estimate of ($0.42). Revenue for the quarter came in at $73.1 million versus the consensus estimate of $72.2 million.

For earnings history and earnings-related data on Collegium Pharma (COLL) click here.